SPONSORED

Pharma Conglomerate Cosmos Holdings (OTC: COSM) Reported Record Revenue Growth of Approximately 40% For 2020(1)

Calling This Company a Disruptor in an Estimated $1.3 Trillion Global Pharma Industry(2) Could Be a Colossal Understatement

April 16, 2021:
Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020

You’ve probably heard enough about biotech innovators and Big Pharma’s impact on our world over the last 12+ months or so. After all, we’re living through an unprecedented health situation.

But get this. It’s not like our health needs will just disappear overnight. In fact, we’ll probably have a renewed focus on how essential health and wellness are with the global health scare ebbing and flowing.

In fact, according to Fortune Business Insights, in 2020, the health scare “accelerated the demand for effective treatments and dr-ugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion.(2)

However, this may not be a short-term growth trend. A subsequent report from Fortune Business Insights claims that amid the health scare, there is an “increasing prevalence of chronic disease and the growing adoption of modern technologies that are leading to the evolving pharmaceuticals sector.”(3) This is why Fortune believes we could see the global pharmaceuticals market size reach nearly $2.15 trillion by 2027 at an estimated CAGR of 7.0%.(3)

But while you were reading about the Pfizers, Modernas, JnJs, and AstraZenecas of the world, I came across this Chicago-based Pharmaceutical Holding Company called Cosmos Holdings (OTC: COSM). If you aren’t familiar with this firm and have your mind wrapped about vaccines and health complications, it’s time you get acquainted with this company now.

As the world continues to evolve thanks to the current situation, Cosmos Holdings (OTC: COSM) offers customers and shareholders diversified exposure to several in-demand and growing verticals in the pharma and wellness space, including(4)

  • Branded Pharmaceuticals
  • Generic Pharmaceuticals
  • Health Products & Food Supplements
  • Research & Development
  • Acquisitions
  • Green leaf derived products
  • Local & Direct to Pharmacy Wholesale

Clearly, this company and its unique business model may be doing something right too. After all, not all pharma conglomerates for the fiscal year 2020 reported record revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%.(2)

As we continue walking a tightrope between a once-in-a-century health scare and going back to some semblance of normalcy, there is simply so much to love about Cosmos Holdings (OTC: COSM). 

The Top Reasons to Consider Cosmos Holdings (OTC: COSM)

  1. According to Fortune Business Insights, the health scare in 2020 “accelerated the demand for effective treatments and dr-ugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion.(2)
  2. An increasing prevalence of chronic disease and growing adoption of modern technologies could help the global pharma market hit nearly $2.15 trillion by 2027 at an estimated 7.0% CAGR.(3)
  3. Cosmos Holdings (OTC: COSM), a fully reporting Pharmaceutical Holding Company, could be as well-positioned as anyone to capitalize on a growing pharma industry with diversified operations across many different verticals, with its subsidiaries, with new products coming to market.
  4. Cosmos has an extensive network of over 160 clients and vendors in Germany, the United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece.(12)
  5. The foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses. On the other hand, its sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its development and position in the pharmaceutical supply channel.(4)
  6. Cosmos has finite knowledge and exposure to pharma sectors all across the supply chain, including Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, Acquisitions, Green leaf derived products, and Local & Direct to Pharmacy Wholesale.(4)
  7. Ever since February 2021, Cosmos has announced the launch of three potentially game-changing products for bone function(9), libido(10), and an oral spray designed to be effective against bacteria and other pathogens.(11)
  8. For the fiscal year 2020, Cosmos reported record revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%.(2)
  9. With bullish technicals, the COSM stock has advanced a potential 195.12% over the last 12-months(5) and approximately 315.03% from its 12-month low of about $1.53 to its 12-month high of roughly $6.35.(6)
  10. Cosmos leadership team consists of high-quality experts with unique experiences all across various business sectors.

From Technicals to Fundamentals, Cosmos Holdings (OTC: COSM) Looks Like a Bullish Juggernaut

The last 12 months have been extremely strong for Cosmos Holdings. On April 27, 2020, the COSM stock closed at just about $2.00 a share. Now, a year later, as of April 26, 2021, the stock closed at roughly $6.05 a share.

You do the math. Over the last year, we saw a stock whose price potentially multiplied more than 3x while advancing about 195.12%.

Not to mention, if you take the stock’s 12-month low of about $1.53, and 12-month high of roughly $6.35, you’ll see a potential vertical surge of 315.03%.(6)

Almost all of the company’s technical indicators in the short-,medium-, and long-term look bullish as well, such as its 20 Day Moving Average, 20 – 50 Day MACD Oscillator, 20 – 100 Day MACD Oscillator, 20 – 200 Day MACD Oscillator, 50 Day Moving Average, 50 – 100 Day MACD Oscillator, 50 – 150 Day MACD Oscillator, 50 – 200 Day MACD Oscillator, 100 Day Moving Average, 150 Day Moving Average, 200 Day Moving Average, and 100 – 200 Day MACD Oscillator.(7)

The company has a lot going for it on the fundamental side of the equation too. COSM’s latest earnings report for the full year ended December 31, 2020 was nothing short of jaw-dropping:(2)

  • Revenue for 2020 increased approximately 40% to $55.4 Million, compared to $39.7 for the same period last year
  • Gross profit for 2020 increased an estimated 120% to $8.1 million, versus $3.7 million for 2019
  • Operating income improved by roughly $3.0 million to $2.7 million, compared to an operating loss of $0.3 million for the same period last year.
  • Net income attributable to common stockholders was approximately $0.8 million, or $0.06 per share for 2020, compared to net loss of $3.3 million or ($0.25) per share for 2019

Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated, “I am pleased to report we generated 40% year-over-year revenue growth and achieved profitability for 2020 despite the impact of the health predicament on the global markets. We have successfully navigated the health scare and are on a solid growth trajectory heading into 2021. Our proprietary line of nutraceuticals and food supplements, Sky Premium Life, continues to expand and we now have over 70 SKUs. We expect to reach 150 SKUs by the end of 2021 and believe the recent as well as upcoming additions to our portfolio will become major drivers of our growth going forward. In addition to introducing new high margin pharmaceutical, nutraceutical and food supplement products, we have built a robust distribution network, which now includes relationships with over 160 wholesale pharmaceutical distributors across Europe’s largest markets, having access to over 40,000 pharmacies. In addition, we plan to expand to new global markets later this year.”(2)

Siokas further added, “Overall, we have built a highly scalable business model and look forward to further enhancing profitability and cash flow as we leverage our fixed cost infrastructure and gain economies of scale. We have invested in and now operate 3 state-of-the-art warehouses with advanced automation technology that substantially expands our current capacity and throughput to support our planned growth. We remain highly encouraged by the outlook for the business and look forward to providing further updates as developments unfold.”(2)

Who is Cosmos Holdings (OTC: COSM)?

Cosmos Holdings Inc. is a fully reporting Pharmaceutical Holding Company based in Chicago, Illinois, USA, that specializes, through its subsidiaries, in the wholesale of pharmaceutical products throughout Europe. The company is focused on identifying, acquiring, developing, and commercializing different medicines to improve patients’ lives. Cosmos has an extensive network of over 160 clients and vendors in Germany, the United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece. Not to mention, Cosmos has offices and distribution centers in Thessaloniki, Greece, and Harlow, UK.

Cosmos Holdings (OTC: COSM) Has a Comprehensive Strategy

The foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses.  As Cosmos continues devoting significant resources to improve its operating and capital efficiencies, the company believes it’s well-positioned in size and market breadth to continue growing its trading businesses.

Sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its growth and position in the pharmaceutical supply channel. Cosmos provides superior services and delivers value-added products, which improve the efficiency and competitiveness of healthcare providers. In turn, this aids the pharmaceutical supply channel to better provide healthcare to patients.

Specific areas of Cosmos (OTC: COSM) focus include the following:(4)

Branded Pharmaceuticals: Branded pharmaceutical products are the primary product category that Cosmos imports and exports. The company constantly evaluates product availability, pricing, demand trends, and patent expirations to maximize our performance. As the patents for branded products near expiration, the generic equivalents enter the marketplace. Thus, demand for those branded products starts to decrease. Cosmos monitors these cycles closely and always looks to find value in pricing fluctuations caused by the patent expirations as the generic equivalents enter the market.

Generic Pharmaceuticals: Generic pharmaceutical products are the secondary product category that Cosmos imports and exports. The company applies the same discipline to generics that it does with the branded. Just as with branded products, Cosmos is continuously evaluating the supply/demand as patents expire. This insight sheds light on the demand for generic products that take their place. Understanding the historical and market-specific characteristics of generic product demand provides insight that Cosmos uses to give guidance to its vendors that source its generic drug exports.

Health Products & Food Supplements: The wholesale distribution of food supplements actually offer more significant margins than pharmaceutical product distribution. Cosmos is always looking to expand the portfolio of products that we distribute to maximize our margins. It also conveniences Cosmos’ customer base by providing them a more extensive portfolio of products that they can source from a single vendor.

In addition to being wholesalers for supplements and related products, Cosmos is also creating its own product brand. Cosmos’ wholesale business gives it insight into what products are in demand. It also communicates with its customer base to identify which products to develop. With this strategy, Cosmos’ own brand of products may potentially carry significantly higher margins than simply serving as a wholesaler for other brands.

Research & Development: Cosmos is committed to strategic R&D across each business unit with a particular focus on nutraceutical products with inherently lower risk profiles and clearly defined regulatory pathways. The company constantly evaluates the demand for food supplements in the markets where it currently distributes pharmaceutical products. This research and analysis determines which food and nutritional supplements Cosmos chooses to develop and their formulations. This approach aims to maximize the probability of successfully competing with other brands in the marketplace.

Acquisitions: Cosmos regularly evaluates acquisition targets that could expand its distribution reach and/or vertically integrate into the supply chain of the products that it currently distributes. In addition to focusing on organic growth drivers, the company is also actively pursuing accretive acquisitions that offer long-term revenue growth, margin expansion through synergies, and the ability to maintain a flexible capital structure.

Green Leaf-derived products: Cosmos closely monitors the legal framework for prescription and nonprescription derivatives of green leaf products as it develops in Europe. As the legal framework and processes are developed and implemented in each respective EU country, Cosmos plans to utilize its existing network to distribute both prescription and nonprescription derivatives of green leaf products to its current customer base. For the time being, Cosmos currently intends to only distribute prescription and nonprescription derivatives of green leaf products to approved EU countries and not in the US.

Local & Direct to Pharmacy Wholesale: Cosmos is also expanding into the full-line wholesale distribution business through acquisitions. Full-line pharmaceutical wholesalers provide the local markets with branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) medicines, vitamins, and food supplements. By expanding its pharmaceutical distribution business, Cosmos believes that it will have a better ability to directly source more branded and generic products from manufacturers. That way, Cosmos can potentially sell its vitamins, food supplements, and cosmetic products directly to pharmacies for better prices. The company expects this expansion to increase its sales and profit margins as it vertically integrates into the supply chain.

Cosmos (OTC: COSM) is also very well known for the following 3 subsidiaries under its belt:(8)

  Sky Pharm SA: Sky Pharm SA is a Thessaloniki, Greece-based pharmaceutical trading firm. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. Cosmos buys from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers and then exports them to European markets where demand and prices are substantially higher. The company is in compliance with GDP (Good Distribution Practices) certified by the Greek equivalent to the FDA and was also ISO certified by TUV NORD in Feb. 2016.

DHNDecahedron Ltd.: Decahedron Ltd. is a UK-incorporated pharmaceutical wholesaler. It is audited by the MHRA under European GDP (Good Distribution Practices). It is also a full member of the EAEPC and has been audited by TÜV on its behalf. Decahedron imports and exports branded, generic and unlicensed POM, OTCs, and medical devices worldwide. It also participates in governmental tenders and registers dossiers in new territories. This subsidiary’s network consists of roughly 25 clients and vendors expanding to 9 countries, including Germany, UK, Denmark, United Arab Emirates, Germany, Italy, France, Singapore, and Ireland.

Cosmofarm: Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices to its growing network of more than 1130 pharmacies. The company maintains a vast supplier network of approximately 250 pharmaceutical manufacturers and wholesalers.

Cosmos (OTC: COSM) Has Recently Announced Three Potentially Game-Changing Products

Since February, Cosmos has taken the world by storm as they announced three potentially game-changing products.

First, in February 2021, Cosmos announced the launch of a new, proprietary enhanced dietary supplement, Osteodome. Osteodome is a targeted nutritional supplement specifically designed to support normal bone and cartilage function and joint flexibility.(9)

Osteodome also contributes to(9)

  • the normal formation of collagen in the body
  • the normal formation of connective tissue in the body
  • the normal muscle functions
  • the normal absorption of calcium and phosphorus
  • the protection of cells from oxidative stress (antioxidant)

In April 2021, Cosmos launched two additional exciting products. First, it announced its proprietary King Eros and Queen Venus supplements for enhanced libido(10). Then, it announced the Mosept-Oral Antiseptic Spray, a spray designed to be effective against bacteria and other pathogens.(11)

King Eros, first and foremost, is a complete food supplement designed for men with carefully selected natural botanical extracts, amino acids, vitamins, and minerals.(10) At the same time, Queen Venus is a complete nutritional supplement designed for women with carefully selected herbal extracts, vitamins, minerals, trace elements, and amino acids.(10) Both products are initially being placed in approximately 1,700 pharmacies across Greece and in Holland & Barrett stores in Cyprus.(10) Cosmos also expects to have the products placed in 1,500 more pharmacies by the end of the year, with plans to expand to the UK, Germany, Canada, and China in the near term.(10)

The Mosept-Oral Antiseptic Spray is also an easy-to-use spray designed for customers to use anywhere, anytime they may feel throat irritation or infection. This product is designed with a cutting-edge proprietary formula for the symptomatic relief of pain and irritated sore throat. Cosmos plans to launch it in 3,500 pharmacies in Greece, with plans to expand to the UK, Germany, the Netherlands, France, Italy, Spain, Cyprus, Canada, and the Middle East.(11)

A High-Quality Team Also Leads Cosmos Holdings (OTC: COSM)

Grigorios Siokas
Chairman, CEO, CFO & Principal Accounting Officer

Mr. Grigorios Siokas has over 15 years of experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA, a wholly-owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England, and Denmark.

Before 2014, Mr. Siokas worked in various pharmaceutical industry sectors, mainly in trading medicines in Greece and other European countries. Additionally, since 2000 he has been a significant shareholder in different pharmaceutical companies such as Ippokratis Pharmaceuticals (annual sales of over € 78 million); Thrakis Pharmaceuticals (annual sales of over € 20 million); Thessalias Pharmaceuticals (annual sales of over € 18 million); and ZED Pharma SA, (annual sales of over € 35 million).

During the 1990s, Mr. Siokas founded and operated a marble wholesale import-export company in Germany. Within two years, he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers.

Mr. Grigorios Siokas has Bachelor’s Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master’s in management and finance from the University of Stuttgart and the University of Tuebingen, Germany, and served in the Greek Army.

Dimitrios Goulielmos
CEO/Director

Dimitrios Goulielmos joined Cosmos as CEO and Director on September 27, 2013. Since January 1991, he has been the principal attorney at the law firm of Goulielmos D. & Partners. He contributes to the Board the benefits of his legal, academic, and business background.

Mr. Goulielmos is a fourth-generation attorney. He received his law degree with Excellency from the Aristotle University of Thessaloniki in 1988. He did post-graduate studies for International transactions and Company law at Paris, France, and at the LSE of London, England.

In 2004 he was elected Vice-president of EUROPECHE. This organization was established by the European Committee for the Consultation and Proposal of Solutions in the Community Fisheries sector.

The same year he was also elected as National representative of Hellas in the MEDISAMAK, the organization responsible for all Mediterranean countries in the Fishery sector.

In the year 2007, he was re-elected as Vice-president of EUROPECHE. He is a member of the social dialogue group of ACFA of EU on labor affairs.

He is an honorary lifetime member of the International Who’s Who Historical Society.

Mr. Goulielmos has extensive law, international deals, mergers, acquisitions, negotiations, global application of licenses, and real estate management experience to contribute to the Board.

Demetrios G. Demetriades
Secretary and Director 

Since January 2003, Mr. Demetriades, age 48, has been Director of Highlander Spring Trading Ltd, a trading company.

From November 2000 to December 2002, he was Marketing Director of Eurolink Securities Ltd, which was involved in trading in the Cyprus Stock Exchange.

From January 1995 to November 2000, he was Supervising Officer of Laiki Factors Ltd, a financing company.

As a board member, Mr. Demetriades contributes the benefits of his trading, executive leadership, and management experience.

John J. Hoidas
Board Member

On November 18, 2016, Cosmos’ Board of Directors appointed John J. Hoidas as a board member. Mr. Hoidas is a registered broker-dealer. Mr. Hoidas has served as a broker for the following firms during the corresponding periods.

09/2013 – Present UHLMANN INVESTMENT MANAGEMENT

09/2013 – Present UHLMANN PRICE SECURITIES, LLC

08/2008 – Present BREWER INVESTMENT GROUP CHICAGO, IL

11/2010 – 09/2013 KINGSBURY CAPITAL INVESTMENT ADVISORS

11/2010 – 09/2013 KINGSBURY CAPITAL LLC

11/2010 – 09/2013 SPENCER TRASK VENTURES

John J. Hoidas began working on the CME floor in 1989 as a runner and, by 1995, started trading the S&P 500 and GSCI Index Futures for 9 years. He then moved to Wealth Management, starting with American Express Financial Advisors, which spun off to Ameriprise. He then moved to Kingsbury Capital in 2010. There, he began raising money for late-stage pre-IPO companies such as Organovo, Invivo Therapeutics, and Matinas BioPharma, to name a few. Currently, John is the Senior Vice President at Uhlmann Price, a firm he joined in 2013. Since joining Uhlmann Price Securities, he has raised capital for startups such as Video Gaming Co; Gazillion, Inc., LiquidSpace, and Revel Systems.

Peter Goldstein
Executive Director

Peter Goldstein was elected Executive Director of the Company on October 15, 2020. Peter Goldstein, age 58, has over 30 years of diverse and global entrepreneurial, client advisory, and capital market experience. With a background in international business, he has worked across various markets and industries, holding positions including investment banker, chairman, chief executive officer, and advisor to public, private, and emerging growth companies. Goldstein has achieved capital market objectives by drawing on his strengths in M&A, strategic planning, and transaction structuring, as well as his own entrepreneurial success. He has steered and completed initial public offerings (IPO), uplisting and reverse merger transactions, secured private placements, and designed successful crowdfunding campaigns. In July 2018, he founded Exchange Listing, LLC to provide growth companies with a cost-effective one-stop strategic planning and implementation service to list on senior exchanges such as NASDAQ, NYSE, and NEO. In his most recent advisory success, Mr. Goldstein advised on Siyata Mobile upsized $12.6 Million U.S. Initial Public Offering and listing on the NASDAQ, which closed in September 2020. Mr. Goldstein is the founder and chief executive officer of Grandview Capital Partners, Inc. This company has provided M&A, financial, operational, and organizational consulting services to worldwide businesses across numerous industries. He previously founded Grandview Capital, Inc., a boutique investment bank, where he served as managing director of investment banking. In addition to advising other businesses, Goldstein launched and successfully grew several of his own companies. He was Co-Founder and chairman of the board of Staffing 360 Solutions, Inc., an emerging public company in the international staffing sector engaged in acquiring domestic and international staffing agencies. He began his entrepreneurial career as founder and CEO of a specialty food distributor, which pioneered the farm-to-table organic produce industry in top-tier New York City restaurants. Mr. Goldstein has an MBA in International Business from the University of Miami and holds Series 7, 24,79, 99, and 66 registrations with FINRA.

The Top Reasons to Consider Cosmos Holdings (OTC: COSM)

  1. According to Fortune Business Insights, the health scare in 2020 “accelerated the demand for effective treatments and dr-ugs worldwide” and caused the global pharmaceutical industry to reach an estimated valuation of $1.3 Trillion.(2)
  2. An increasing prevalence of chronic disease and growing adoption of modern technologies could help the global pharma market hit nearly $2.15 trillion by 2027 at an estimated 7.0% CAGR.(3)
  3. Cosmos Holdings (OTC: COSM), a fully reporting Pharmaceutical Holding Company, could be as well-positioned as anyone to capitalize on a growing pharma industry with diversified operations across many different verticals, with its subsidiaries, with new products coming to market.
  4. Cosmos has an extensive network of over 160 clients and vendors in Germany, the United Kingdom, United Arab Emirates, Denmark, Italy, France, Singapore, Ireland, Sweden, Poland, Netherlands, and Greece.(12)
  5. The foundation of Cosmos’ operating strategy is the optimization and growth of its pharmaceutical sourcing and distribution businesses. On the other hand, its sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its development and position in the pharmaceutical supply channel.(4)
  6. Cosmos has finite knowledge and exposure to pharma sectors all across the supply chain, including Branded Pharmaceuticals, Generic Pharmaceuticals, Health Products & Food Supplements, Research & Development, Acquisitions, Green leaf derived products, and Local & Direct to Pharmacy Wholesale.(4)
  7. Ever since February 2021, Cosmos has announced the launch of three potentially game-changing products for bone function(9), libido(10), and an oral spray designed to be effective against bacteria and other pathogens.(11)
  8. For the fiscal year 2020, Cosmos reported record revenue growth of about 40% and jaw-dropping gross profit growth of nearly 120%.(2)
  9. With bullish technicals, the COSM stock has advanced a potential 195.12% over the last 12-months(5) and approximately 315.03% from its 12-month low of about $1.53 to its 12-month high of roughly $6.35.(6)
  10. Cosmos leadership team consists of high-quality experts with unique experiences all across various business sectors.
Source 1: https://finance.yahoo.com/news/cosmos-holdings-reports-revenue-growth-131500696.html?.tsrc=rss
Source 2: https://bit.ly/3sTk48z
Source 3: https://bit.ly/3vnYLh4
Source 4: https://www.cosmosholdingsinc.com/company/strategy
Source 5: https://yhoo.it/3gEZ1Ej
Source 6: https://finance.yahoo.com/quote/COSM?p=COSM
Source 7: https://www.barchart.com/stocks/quotes/COSM/opinion
Source 8: https://www.cosmosholdingsinc.com/subsidiaries
Source 9: https://finance.yahoo.com/news/cosmos-holdings-launches-osteodome-eu-023500498.html?.tsrc=rss
Source 10: https://finance.yahoo.com/news/cosmos-holdings-launches-proprietary-king-131600196.html?.tsrc=rss
Source 11: https://finance.yahoo.com/news/cosmos-holdings-launches-mosept-oral-140500055.html?.tsrc=rss
Source 12: https://www.cosmosholdingsinc.com/

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

COMPENSATION